Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon α-2b

L. Bíró, L. Varga, A. Pár, E. Nemesánszky, A. Csepregi, L. Telegdy, E. Ibrányi, K. Dávid, G. Horváth, L. Szentgyörgyi, I. Nagy, L. Dalmi, M. Abonyi, G. Füst, M. Horányi

Research output: Article

14 Citations (Scopus)

Abstract

In order to study the effect of interferon alpha on the levels of acute phase complement proteins in vivo, serum concentrations of C9 and C1- inhibitor (C1-INH) were measured in patients with chronic hepatitis C before and 3 months after the beginning of interferon α2b therapy. Serum levels of the activation product of terminal complement pathway, C5b-9, HCV RNA and IL- 6 were also determined. IFN alpha treatment significantly (P <0.0001) increased the serum concentrations of both complement proteins. C5b-9 levels were found to significantly decrease during the same period of time. When the patients were divided into responders or non-responders (more or less than 50% decrease in plasma HCV RNA concentrations) C9 and C1-INH levels were elevated only in the responder patients. There was no correlation between the changes of IL-6 levels or the amounts of IFN alpha administrated on one hand, and the changes in the complement protein levels on the other. These findings suggest that the marked increase in the serum concentrations of the acute phase complement proteins is a secondary phenomenon due to the IFN alpha- caused diminution of the viral load and the resulting immune complex-induced complement activation. (C) 2000 Published by Elsevier Science B.V.

Original languageEnglish
Pages (from-to)69-74
Number of pages6
JournalImmunology Letters
Volume72
Issue number2
DOIs
Publication statusPublished - máj. 1 2000

Fingerprint

Complement C6
Chronic Hepatitis C
Interferons
Interleukin-6
Complement System Proteins
Complement Membrane Attack Complex
Acute-Phase Proteins
Serum
Complement C5b
RNA
Complement Activation
Antigen-Antibody Complex
Viral Load
Interferon-alpha
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon α-2b. / Bíró, L.; Varga, L.; Pár, A.; Nemesánszky, E.; Csepregi, A.; Telegdy, L.; Ibrányi, E.; Dávid, K.; Horváth, G.; Szentgyörgyi, L.; Nagy, I.; Dalmi, L.; Abonyi, M.; Füst, G.; Horányi, M.

In: Immunology Letters, Vol. 72, No. 2, 01.05.2000, p. 69-74.

Research output: Article

Bíró, L, Varga, L, Pár, A, Nemesánszky, E, Csepregi, A, Telegdy, L, Ibrányi, E, Dávid, K, Horváth, G, Szentgyörgyi, L, Nagy, I, Dalmi, L, Abonyi, M, Füst, G & Horányi, M 2000, 'Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon α-2b', Immunology Letters, vol. 72, no. 2, pp. 69-74. https://doi.org/10.1016/S0165-2478(00)00183-8
Bíró, L. ; Varga, L. ; Pár, A. ; Nemesánszky, E. ; Csepregi, A. ; Telegdy, L. ; Ibrányi, E. ; Dávid, K. ; Horváth, G. ; Szentgyörgyi, L. ; Nagy, I. ; Dalmi, L. ; Abonyi, M. ; Füst, G. ; Horányi, M. / Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon α-2b. In: Immunology Letters. 2000 ; Vol. 72, No. 2. pp. 69-74.
@article{f52d9f0ec27b4759afcf016094b43e84,
title = "Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon α-2b",
abstract = "In order to study the effect of interferon alpha on the levels of acute phase complement proteins in vivo, serum concentrations of C9 and C1- inhibitor (C1-INH) were measured in patients with chronic hepatitis C before and 3 months after the beginning of interferon α2b therapy. Serum levels of the activation product of terminal complement pathway, C5b-9, HCV RNA and IL- 6 were also determined. IFN alpha treatment significantly (P <0.0001) increased the serum concentrations of both complement proteins. C5b-9 levels were found to significantly decrease during the same period of time. When the patients were divided into responders or non-responders (more or less than 50{\%} decrease in plasma HCV RNA concentrations) C9 and C1-INH levels were elevated only in the responder patients. There was no correlation between the changes of IL-6 levels or the amounts of IFN alpha administrated on one hand, and the changes in the complement protein levels on the other. These findings suggest that the marked increase in the serum concentrations of the acute phase complement proteins is a secondary phenomenon due to the IFN alpha- caused diminution of the viral load and the resulting immune complex-induced complement activation. (C) 2000 Published by Elsevier Science B.V.",
keywords = "C1-INH, C9, Complement, HCV, IFN alpha, Il-6",
author = "L. B{\'i}r{\'o} and L. Varga and A. P{\'a}r and E. Nemes{\'a}nszky and A. Csepregi and L. Telegdy and E. Ibr{\'a}nyi and K. D{\'a}vid and G. Horv{\'a}th and L. Szentgy{\"o}rgyi and I. Nagy and L. Dalmi and M. Abonyi and G. F{\"u}st and M. Hor{\'a}nyi",
year = "2000",
month = "5",
day = "1",
doi = "10.1016/S0165-2478(00)00183-8",
language = "English",
volume = "72",
pages = "69--74",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon α-2b

AU - Bíró, L.

AU - Varga, L.

AU - Pár, A.

AU - Nemesánszky, E.

AU - Csepregi, A.

AU - Telegdy, L.

AU - Ibrányi, E.

AU - Dávid, K.

AU - Horváth, G.

AU - Szentgyörgyi, L.

AU - Nagy, I.

AU - Dalmi, L.

AU - Abonyi, M.

AU - Füst, G.

AU - Horányi, M.

PY - 2000/5/1

Y1 - 2000/5/1

N2 - In order to study the effect of interferon alpha on the levels of acute phase complement proteins in vivo, serum concentrations of C9 and C1- inhibitor (C1-INH) were measured in patients with chronic hepatitis C before and 3 months after the beginning of interferon α2b therapy. Serum levels of the activation product of terminal complement pathway, C5b-9, HCV RNA and IL- 6 were also determined. IFN alpha treatment significantly (P <0.0001) increased the serum concentrations of both complement proteins. C5b-9 levels were found to significantly decrease during the same period of time. When the patients were divided into responders or non-responders (more or less than 50% decrease in plasma HCV RNA concentrations) C9 and C1-INH levels were elevated only in the responder patients. There was no correlation between the changes of IL-6 levels or the amounts of IFN alpha administrated on one hand, and the changes in the complement protein levels on the other. These findings suggest that the marked increase in the serum concentrations of the acute phase complement proteins is a secondary phenomenon due to the IFN alpha- caused diminution of the viral load and the resulting immune complex-induced complement activation. (C) 2000 Published by Elsevier Science B.V.

AB - In order to study the effect of interferon alpha on the levels of acute phase complement proteins in vivo, serum concentrations of C9 and C1- inhibitor (C1-INH) were measured in patients with chronic hepatitis C before and 3 months after the beginning of interferon α2b therapy. Serum levels of the activation product of terminal complement pathway, C5b-9, HCV RNA and IL- 6 were also determined. IFN alpha treatment significantly (P <0.0001) increased the serum concentrations of both complement proteins. C5b-9 levels were found to significantly decrease during the same period of time. When the patients were divided into responders or non-responders (more or less than 50% decrease in plasma HCV RNA concentrations) C9 and C1-INH levels were elevated only in the responder patients. There was no correlation between the changes of IL-6 levels or the amounts of IFN alpha administrated on one hand, and the changes in the complement protein levels on the other. These findings suggest that the marked increase in the serum concentrations of the acute phase complement proteins is a secondary phenomenon due to the IFN alpha- caused diminution of the viral load and the resulting immune complex-induced complement activation. (C) 2000 Published by Elsevier Science B.V.

KW - C1-INH

KW - C9

KW - Complement

KW - HCV

KW - IFN alpha

KW - Il-6

UR - http://www.scopus.com/inward/record.url?scp=0342424383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342424383&partnerID=8YFLogxK

U2 - 10.1016/S0165-2478(00)00183-8

DO - 10.1016/S0165-2478(00)00183-8

M3 - Article

C2 - 10841940

AN - SCOPUS:0342424383

VL - 72

SP - 69

EP - 74

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

IS - 2

ER -